1. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial. (June 2017) Authors: Zinzani, P.; Thieblemont, C.; Melnichenko, V.; Osmanov, D.; Bouabdallah, K.; Walewski, J.; Majlis, A.; Fogliatto, L.; Caballero Barrigón, M.D.; Christian, B.; Gulbas, Z.; Özcan, M.; Salles, G.A.; Shipp, M.A.; Balakumaran, A.; Chlosta, S.; Chatterjee, A.; Armand, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B‐CELL LYMPHOMA TREATED WITH DOSE‐ADJUSTED EPOCH‐R THERAPY: a MULTICENTER RETROSPECTIVE ANALYSIS. (June 2017) Authors: Roth, L.G.; O'Donohue, T.; Chen, Z.; Bartlett, N.; Martin‐Doyle, W.; Barth, M.J.; Davies, K.; Christian, B.; Casulo, C.; Godfrey, J.; Oberley, M.J.; Alexander, S.; Weitzman, S.; Appel, B.; Svoboda, J.; Afify, Z.; Pauly, M.; Dave, H.; Gardner, R.; Stephens, D.M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗